A range of speakers from government, regulators and the industry lay out at the BioJapan meeting in Yokohama the major ...
FDA staff said the move to allow compounding of some unapproved peptide products raises patient safety concerns and weakens ...
Results from a comparison of mifepristone's safety to surgical abortion are expected in December with a final report in March ...
Leaders in the cell therapy field talked about how to expand access to CAR-T cell therapy, with one exec saying bringing it ...
Medical Microinstruments raised $125m in Series D funding, led by BioStar Capital. The firm will use the funds to expand ...
Former US FDA advisory committee chair Eric Brass told the AESGP switch conference in Brussels that switch decisions focus ...
The successor to Emer Cooke as head of the European Medicines Agency could be identified soon, with the successful candidate ...
Analysts see a role for the amylin agonist thanks to placebo-like tolerability, but Lilly and Novo candidates in the class ...
The German group is hoping to get the green light for the mineralocorticoid receptor antagonist for adults with chronic ...
Edwards and Highlife’s mitral valve replacement systems will receive health technology assessment (HTA) at an EU level via a ...
First And Likely Only Entrant In US FDA’s Split Real-Time Review Pilot Is Arrowhead’s Plazosiran
Arrowhead's severe hypertriglyceridemia (sHTG) filing for Redemplo is the first known entry into the FDA's STAR pilot, an ...
Investors at the Cell & Gene Meeting on the Mesa expressed concern, though it may be a while before China can become a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results